Clinical trial NCT05223179: Intramuscular CodaVax-H1N1 in Healthy Adults
Official title: Randomised, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability, and Immunogenicity of Intramuscular CodaVax-H1N1 in Healthy Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Influenza, Human
Keywords: Influenza, Human
Viral Vaccines
Vaccines, Live Attenuated
Lead sponsor: Codagenix, Inc
Sponsor class: INDUSTRY
First posted: 2022-02-03
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study is a Phase 1, 2-part, randomised, double-blind, controlled, clinical trial to evaluate the safety and immune response of CodaVax-H1N1 in healthy adults aged 18 to 49 years. Participants will be enrolled in autumn 2022 (southern hemisphere) and followed through the 2022 influenza season (Part A) or enrolled in autumn 2023 and followed through the 2023 influenza season (Part B). Participants will be screened within 28 days of randomization, and eligible participants in Part A will be enrolled into 1 of 3 sequential cohorts and randomised to receive a single dose of CodaVax-H1N1, placebo (normal saline), or licenced injectable seasonal influenza vaccine (Flucelvax Quad). Each subsequent cohort will include a higher dose of CodaVax H1N1 than the previous cohort, in addition to placebo and the licensed injectable seasonal influenza vaccine. In Part B, 24 eligible participants will be enrolled into 1 of 2 sequential cohorts and randomised to receive a single IM dose of CodaVax-H1N1 or placebo.

Detailed description: This study is a Phase 1, 2-part, randomised, double-blind, controlled, clinical trial to evaluate the safety and immune response of CodaVax-H1N1 in healthy adults aged 18 to 49 years. Participants will be enrolled in autumn 2022 (southern hemisphere) and followed through the 2022 influenza season (Part A) or enrolled in autumn 2023 and followed through the 2023 influenza season. Participants will be screened within 28 days of randomization, and eligible participants in Part A will be enrolled into 1 of 3 sequential cohorts and randomised to receive a single dose of CodaVax-H1N1, placebo (normal saline), or licensed injectable seasonal influenza vaccine (Flucelvax Quad). Each subsequent cohort will include a higher dose of CodaVax H1N1 than the previous cohort, in addition to placebo and the licensed injectable seasonal influenza vaccine. In Part B, 24 eligible participants will be enrolled into 1 of 2 additional sequential cohorts and randomised to receive a single IM dose of CodaVax-H1N1 or placebo.

Participants will record reactogenicity events (local events, systemic events, and temperature) in a daily diary for 7 days after the dose. Each participant will be contacted by telephone on the day after dosing for safety assessment and review of the diary data. Participants will return to the clinic on Days 4, 8, 29, 91, and 181 for safety and immune response assessments.

All adverse events and concomitant medications will be recorded from signing of the informed consent form (ICF) to 28 days postdose. After 28 days until the end of the study, only medically attended adverse events (MAAEs), new onset chronic illnesses (NCIs), serious adverse events (SAEs), immunosuppressive medications, blood products like transfusions or infusions, and vaccines will be recorded. A complete physical examination will be performed at Screening, and targeted and symptom-driven physical examinations will be performed predose on Day 1, 2 hours postdose, and at each postdose visit through Day 91. Vital signs will be measured at the same time points. An electrocardiogram (ECG) will be performed at Screening and on Day 29.

A serum sample will be collected predose and on Days 29, 91, and 181 for measurement of immune response.

A whole blood sample will be collected predose and on Day 8 and PBMCs isolated for measurement of T-cell response.

If a participant experiences acute symptoms compatible with viral respiratory infection, nasopharyngeal swab samples will be collected for a rapid influenza diagnostic test and respiratory virus PCR assay panel (including SARS-CoV-2) as indicated for symptomatic respiratory infection and will perform the rapid influenza diagnostic test.

The primary analysis of study data will be conducted after all participants complete the Day 29 visit. The final analysis will be conducted at the end of the study.

Eligibility criteria: Inclusion Criteria:

* Body mass index (BMI) ≥ 18 and ≤ 35 kg/m2
* In good health with no history, or current evidence, of clinically significant medical conditions
* Negative SARS-CoV-2 test predose on Day 1
* For all women, negative pregnancy test
* Agreement to comply with conditions to prevent the spread of genetically modified organisms (GMOs)

Exclusion Criteria:

* Pregnant or lactating women or women who plan to become pregnant through Day 29
* Inadequate venous access for repeated phlebotomy
* History of severe reaction to vaccination
* Receipt of any licenced or investigational influenza vaccine within 6 months before Day 1
* Receipt of any live vaccine within 30 days before Day 1
* Tattoo, skin reaction, or other condition at the injection site that would interfere with assessment of local reactogenicity

Primary outcomes:
measure: Safety and Tolerability by Assessing Percentage of Participants with Reactogenicity Events
timeFrame: Reactogenicity events from Day 1 to Day 7
measure: Safety and Tolerability by Assessing Percentage of Participants with Adverse Events
timeFrame: Adverse events (AEs) from Day 1 to Day 29
measure: Safety and Tolerability by Assessing Percentage of Participants with MAAEs, NCIs, and SAEs.
timeFrame: MAAEs, NCIs, SAEs from Day 1 to Day 181
Secondary outcomes:
measure: Humoral Immunogenicity
timeFrame: HAI assay titre against A/California/07/2009 and the current seasonal influenza vaccine H1N1 and H3N2 strains measured in samples collected on Days 1, 29, 91, and 181
Other outcomes:
Locations:
city: Morayfield
country: Australia
facility: Lis Gilmour, Senior Project Manager
state: Queensland
Study officials:
References: